Geron Corporation

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

Geron Corporation will release its third quarter 2026 financial results and business highlights before market open on Wednesday, November 4, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time the same morning, with an archived webcast available through its investor relations site. This is a scheduling notice only and contains no financial results; Geron is a commercial-stage hematology biotech whose marketed product is RYTELO (imetelstat) for lower-risk MDS.

•11d ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron granted inducement stock options on 570,000 shares to three newly hired employees, effective October 16, 2026, under Nasdaq Listing Rule 5635(c)(4). The options carry a $1.17 exercise price (equal to the grant-date close), a ten-year term, and standard four-year vesting. This is routine equity compensation boilerplate with no bearing on Geron's commercial or clinical trajectory.

•13d ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron granted stock options to purchase an aggregate of 821,250 shares to nine newly hired employees as an inducement material to their acceptance of employment, effective September 17, 2026. The options carry a $1.32 exercise price equal to the grant-date closing price, a ten-year term, and four-year vesting, with 12.5% vesting at the six-month anniversary and the remainder in equal installments over the following 42 months. The awards were made by the Compensation Committee under Geron's 2018 Inducement Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4) — standard new-hire equity compensation with no bearing on the company's commercial or clinical trajectory.

•1mo ago

Geron to Present at Upcoming Investor Conferences

Geron Corporation announced that members of its management team are scheduled to participate in two upcoming investor conferences in September 2026. Geron will host a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9 at 8:00 a.m. ET, and a second fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15 at 3:30 p.m. ET, both in New York. Live and archived audio webcasts of the chats will be available through the investor section of Geron's website. The release restates that Geron's commercial product RYTELO (imetelstat) is approved in the US and EU for lower-risk myelodysplastic syndromes, with a pivotal Phase 3 trial in JAK-inhibitor relapsed/refractory myelofibrosis ongoing.

•1mo ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation granted inducement stock options to purchase an aggregate of 311,250 shares to six newly hired employees effective August 17, 2026. The options have an exercise price of $1.53 per share, equal to the closing price on the grant date, and vest over four years. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the company's 2018 Inducement Award Plan.

•2mo ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation granted inducement stock options to purchase 202,500 shares of common stock to five newly hired employees effective July 17, 2026. The options have an exercise price of $1.44 per share, matching the closing price on the grant date, and vest over four years beginning at the six-month anniversary of employment. These awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) and the company's 2018 Inducement Award Plan.

•3mo ago

Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026

Geron Corporation announced it will release its second quarter 2026 financial results before the market opens on Wednesday, August 5, 2026. The company will host a conference call and webcast to discuss the business highlights and results at 8:00 a.m. Eastern Time on the same day. Geron is a commercial-stage biopharmaceutical company focused on blood cancer treatments, including its approved product RYTELO.

•3mo ago

Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman

Constantine Chinoporos, the interim Chief Business Officer of enGene (ENGN), has been appointed Executive Chairman of Rectify Pharmaceuticals effective immediately. The appointment comes as Rectify advances its lead program RTY-406 into Phase 1 clinical development for hepatobiliary diseases, including primary sclerosing cholangitis. Chinoporos's new role at Rectify may alter his responsibilities at enGene, where he has been serving in an interim capacity focused on business development.

•3mo ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees effective June 17, 2026. The options have an exercise price of $1.23 per share, equal to the closing price on the grant date, and vest over four years with a ten-year term. The awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as an inducement material to employment.

•4mo ago

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron granted stock options to purchase 333,750 shares to five newly hired employees as an inducement to employment. The options have an exercise price of $1.29 per share, equal to the closing price on the grant date of May 15, 2026. The awards vest over four years, with 12.5% vesting at six months and the remainder in equal monthly installments, subject to continued employment.

•5mo ago

Geron Plans to Present at Upcoming Investor Conferences

Geron Corporation announced that management will present at the Bank of America Securities 2026 Healthcare Conference on May 12 and the 2026 Stifel Virtual Targeted Oncology Forum on May 20. Live and archived webcasts of the presentations will be accessible through the Investors and Media section of the company's website. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its product RYTELO approved for certain myelodysplastic syndromes.

•5mo ago

Geron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026

Geron Corporation announced it will release its first quarter 2026 financial results before the market opens on Wednesday, May 6, 2026. The company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and business highlights. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its lead asset being the telomerase inhibitor RYTELO.

•6mo ago